Iolyx Therapeutics and Laboratoires Théa enter into agreement over ILYX-002 for the treatment of OSD | Optometry Times - Clinical News
Published on December 8, 2025
Under the terms of the agreement Iolyx Therapeutics has granted Théa exclusive worldwide development and commercialization rights, excluding Asia, to ILYX-002 for the treatment of ocular surface diseases.